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Abstract
Central memory CD8
+ T cells expressing the adhesion molecule CD62L (L-selectin) are potent mediators of anti-cancer
immunity due to their ability to proliferate extensively upon antigen re-stimulation. The interaction of selectin with its
ligands mediates leukocyte rolling along high endothelial venules. Mice deficient in a(1,3) Fucosyltransferase IV and VII
(FtDKO) lack functional L, P and E selectin ligands. Thus, we addressed whether the lack of selectin ligand interactions alters
tumor protection by CD8
+ T cells in FtDKO mice. Listeria monocytogenes-OVA (LM-OVA) infection evoked potent OVA-
specific CD8
+ T cells that proliferated and contracted at similar kinetics and phenotype in FtDKO and wild-type mice.
Additionally, OVA-specific CD8
+ T cells in both mouse strains exhibited similar phenotypic differentiation, in vivo cytolytic
activity and IFN-c expression. However, FtDKO mice succumbed to B16-OVA tumors significantly earlier than wild-type mice.
In contrast, FtDKO mice evoked strong recall memory CD8
+ T cell responses and protection to systemic LM-OVA re-
challenge. The diminished tumor protection in FtDKO mice was not related to defective antigen presentation by dendritic
cells or reduced proliferation of antigen-specific CD8
+ T cells. However, WT or FtDKO OVA-specific CD8
+ T cells showed
significantly reduced ability to traffic to lymph nodes upon adoptive transfer into naı ¨ve FtDKO recipients. Furthermore,
FtDKO OVA-specific CD8
+ T cells displayed poor ability to infiltrate tumors growing in WT mice. These results reveal that
selectin ligand expression on host endothelium as well CD8
+ T cells may be important for their efficient and continued
extravasation into peripheral tumors.
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Introduction
Vaccination represents a promising approach towards tumor
eradication as CD8
+ T cells play an important role in anti-tumor
immunity [1]. Cancer antigen delivered by live bacterial and viral
vectors such as recombinant Listeria monocytogenes, Salmonella
enterica serovar Typhimurium and adenovirus have been effective
at inducing strong CD8
+ T cells against immunogenic tumors like
metastatic melanoma [2–6]. Furthermore, adoptive transfer
therapies involving tumor-antigen specific CD8
+ T cells have
shown cancer regression in clinical trials [1]. Moreover, memory
CD8
+ T cells can vary in both magnitude and quality [7–9] and
generating a central memory population with a high level
expression of CD62L (TCM) yields longer lasting tumor regression
compared to CD62L low effector memory cells (TEM) [10–12]. We
have previously reported that the choice of vaccine adjuvant and/
or vector can also differentially impact the proportion of the two
types of memory CD8
+ T cells; for example Listeria monocyto-
genes generates a predominant CD62L
high central memory cells
[13]. Nevertheless, clinical trials have revealed only a modest
benefit of cancer immunotherapy and new approaches are
required for objectively maximizing CD8
+ T cell longevity,
mobility, functionality and memory responsiveness [1].
CD62L (L-selectin) is a cell surface adhesion molecule found to
be upregulated on naive and memory lymphocytes. It transiently
interacts with selectin ligands on adjacent cells which initiate the
tethering and rolling of lymphocytes along high endothelial
venules, later leading to other firm adhesions that mediate entry
of the lymphocyte into lymphoid tissue [14]. Selectin ligands are
transmembrane glycoproteins that present the carbohydrate
antigen, sialyl Lewis X to their cognate receptors, L,P and E-
selectins [15,16]. The synthesis of functional selectin ligands
requires many post-translational modifications including a termi-
nal fucosylation mediated by a(1,3) Fucosyltransferase IV and VII
[17,18]. Selectin ligand-selectin interactions may be important in
many points in an immune response from the interaction of naive
and memory T cells with high endothelial venules of lymph nodes
to later interactions of activated T cells with activated epithelium
at a site of inflammation. A redistribution of naive CD8
+ T cells
towards non-lymphoid organs occurs when selectin ligand
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that CD62L mediated trafficking of CD8
+ T cells to lymph nodes
may not be necessary for central memory formation [21], it is
unclear whether selectin ligand interactions are necessary for the
maintenance of an anti-tumor CD8
+ T cell response.
We have used a tumor vaccine model, Listeria monocytogenes
expressing Ovalbumin (LM-OVA) vaccination against the B16-
OVA murine melanoma. CD8
+ T cell responses and tumor
protection were studied in wild-type (WT) C57BL/6J or a(1,3)
Fucosyltransferase IV&VII-double deficient (FtDKO) mice lacking
functional L-selectin ligand interactions. We show that FtDKO
mice, similar to WT mice, develop a robust effector antigen
specific CD8
+ T cell response and memory with similar kinetics
and recall ability against bacterial infections. Nevertheless,
FtDKO mice exhibited reduced tumor protection against B16-




LM-OVA induced tumor immunity is compromised in
FtDKO mice
Mice (WT and FtDKO) were vaccinated with LM-OVA and at
days 21, 93 or 126 post-vaccination challenged with B16-OVA
tumor cells. A significant delay in subcutaneous tumor develop-
ment was observed in both FtDKO and WT vaccinated mice
compared to non-vaccinated controls (Fig. 1A, B, C). However,
regardless of the time of tumor challenge, all vaccinated FtDKO
mice succumbed to subcutaneous tumors significantly quicker
relative to vaccinated WT group (p,0.001, 0.0015, 0.003 for
panels a, b and c respectively). In a metastatic model as well,
longer survival after tumor challenge in vaccinated WT mice was
observed relative to FtDKO mice (Fig. 1D); undefined median
survival for the former compared to 95 days for the latter
(p=0.125). On day 15 after metastatic tumor challenge,
vaccinated WT and FtDKO mice harbored similar number of
black foci in the lungs, whereas vaccinated mice exhibited minimal
tumor burden at this early time point (Fig. 1E). The tumor
protection observed in vaccinated mice was antigen dependent as
infection with LM did not afford protection (data not shown).
These data indicate that B16-OVA tumor cells grew subcutane-
ously and metastatically at a similar pace in non-vaccinated
FtDKO and WT mice. However, LM-OVA vaccinated FtDKO
mice showed compromised tumor immunity.
LM-OVA induces a potent CD8
+ T cell response in FtDKO
mice
The frequency of OVA257–264-specific CD8
+ T cells in the
blood was tracked in independent experiments where animals
were vaccinated with LM-OVA and later challenged with B16-
OVA tumor cells on day 21 (Fig. 2A) day 93 (Fig. 2B) or day 126
(Fig. 2C). The frequency of OVA257–264-specific CD8
+ T cells in
FtDKO mice was significantly greater on day 7 post LM-OVA
infection in 2 out of the 3 experiments. Further analysis of seven
independent experiments, confirmed a higher frequency of blood
OVA257–264-specific CD8
+ T cells in FtDKO mice on day 7 post-
infection (Fig. 2D). The CD8
+ T cell contraction was also similar
in both WT and FtDKO mice as the frequency declined from day
7 to 21 (Fig. 2E). Additionally, a low steady frequency of
OVA257–264-specific CD8
+ T cells was detectable in the blood
(,1%) up to 119 days post infection in both mouse strains
(Fig. 2B & C). Upon tumor challenge a notable expansion of
OVA257–264-specific CD8
+ T cells occurred for both mouse
strains. Therefore, upon LM-OVA vaccination, FtDKO mice
exhibited no defect in CD8
+ T cell priming, maintenance or recall
response.
LM-OVA induces a similar phenotype of CD8
+ T cells in
WT and FtDKO mice
Naı ¨ve CD8
+ T cells express high levels of IL-7Ra and CD62L.
Once activated CD8
+ T cells down regulate both receptors, later
on in the memory phase, IL-7Ra is again up-regulated and
CD62L expression may be variable depending on the type of
immunization [22,23]. Effector memory cells (TEM) are IL-
7Ra
highCD62L
low whereas central memory cells (TCM) are IL-
7Ra
highCD62L
high, and the latter phenotype cells afford long-
lasting tumor protection [3]. Therefore we assessed if qualitative
differences existed between the antigen-specific CD8
+ T cells
evoked in WT and FtDKO mice. On day 7 after LM-OVA
infection OVA257–264-specific CD8
+ T cells had a similar low level
expression of IL-7Ra and CD62L in both mouse strains (Fig. 3A)
indicative of an effector response. In the memory phase as well, 93
days after infection, the up-regulation of IL-7Ra and CD62L on
OVA257–264-specific CD8
+ T cells occurred similarly in both
strains of mice (Fig. 3A). At day 101, 8 days after tumor challenge,
the OVA257–264-specific CD8
+ T cell population down-regulated
IL-7Ra and CD62L indicating a return to a predominant effector
phenotype. Furthermore, the proportion of TCM (Fig. 3B), TEM
(Fig. 3C) and CD62L
lowIL-7Ra
low effector (Fig. 3D) CD8
+ T cells
was comparable between WT and FtDKO at each time point.
Thus, FtDKO mice induced CD8
+ T cells of similar kinetics and
phenotypic proportions as that of WT during both the effector and
memory phases of the immune response.
LM-OVA induces functional OVA-CD8
+ T cells in FtDKO
mice
Selectin ligands such as PSGL-1 may be induced on CD8
+ T
cells upon activation [8]. Therefore, we next sought to investigate
whether there was any difference in the functionality of selectin
ligand-deficient FtDKO OVA257–264-specific CD8
+ T cells upon
activation. Within 7 days of infection both WT and FtDKO mice
eliminated nearly 100% of target cells in vivo. Over time, the
killing of target cells waned equally in both strains of mice
indicating contraction of the CD8
+ T cell response (Fig. 3E).
Similarly, the frequency of IFN-c secreting CD8
+ T cells was
similar in both strains of mice in the different tissues (Figs. 3F, G &
H). However, due to low numbers of lymph node cells in FtDKO
mice at later time points, CD8
+ T cell frequencies were not
ascertained in this tissue beyond 50 days. Overall, the lack of long-
term tumor protection in FtDKO mice could not be attributed to
non-functional CD8
+ T cell response.
FtDKO mice effectively control primary LM-OVA infection,
induce a strong recall CD8
+ T cell response and are
protected against a bacterial re-challenge
We next ascertained if LM-OVA infection itself was differen-
tially controlled in FtDKO mice. Bacterial burden was enumer-
ated in the spleen and liver following intravenous infection with
10
4 LM-OVA (Fig. 4A and B). A diminished splenic bacterial
burden was noted in FtDKO mice relative to wild-type on day 1
post-infection whereas no differences in liver bacterial burden
were observed at any time point. This may be attributable to the
increased numbers of neutrophils and monocytes in the spleens of
FtDKO mice relative to other organs that occurs due to lymph
node atrophy. Overall, both strains of mice cleared LM-OVA
infection classically within 5 days. In a separate experiment WT
mice were challenged with a lower dose of LM-OVA (10
3 instead
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4 CFU) resulting in a lower bacterial burden similar to
FtDKO mice 1 day after infection. 21 days after infection they
were challenged with B16-OVA; again WT mice were afforded
longer lasting protection from tumor compared to FtDKO mice
vaccinated with a higher dose (Fig. S2).
In order to test the recall ability of OVA257–264-specific CD8
+ T
cells following initial priming, a re-challenge infection of 10
5 LM-
OVA was done 21 days after initial vaccination. As observed
above, non-vaccinated FtDKO mice had a significantly decreased
splenic bacterial burden compared to WT (Fig. 4C) even to a
higher dose (10
5) of LM-OVA. However, in vaccinated mice, both
FtDKO and WT had undetectable splenic LM-OVA burden upon
re-challenge indicating a rapid secondary response. Concurrently,
the LM-OVA re-challenge caused the rapid expansion of blood
resident OVA257–264-specific CD8
+ T cells in both mouse strains
indicative of a strong memory recall response (Fig. 4D). Thus,
while FtDKO mice exhibited diminished protection against tumor
challenge, their CD8
+ T cell response was effective against
infection re-challenge.
Dendritic cells (DCs) of FtDKO mice induce strong
antigen presentation to CD8
+ T cells
Next, to investigate any potential defect in antigen presentation,
we measured the ability of splenic DCs from LM-OVA infected
mice to present OVA257–264 antigen to CD8
+ T cells ex-vivo.
Successful antigen presentation resulted in robust CD8
+ T cell
proliferation and CFSE dilution (Fig. 5A). DC’s from LM infected
mice lacking in-vivo exposure to antigen served as negative
controls and OVA257–264 peptide pulsed DC’s served as positive
controls. DC’s from FtDKO and WT mice infected with LM-
OVA were capable of inducing CD8
+ T cell proliferation similar
to positive controls (Fig. 5A) as well as rapid CD62L down-
regulation (data not shown). Therefore no intrinsic antigen-
presentation defect in the DCs of FtDKO mice was discerned.
Figure 1. Prophylactic vaccination against B16-OVA/. C57BL/6J (WT) and FtDKO mice were vaccinated intravenously with LM-OVA and
challenged with B16-OVA subcutaneously (A) 21 days, (B) 93 days or (C) 126 days post-infection. Survival curves were based on animals reaching a
tumor size, 200 mm
2. (D), Mice were challenged intravenously with B16-OVA, 21 days post LM-OVA infection. Survival was based on animals
exhibiting a maximum weight loss of 20% or other clinical signs of illness. (E), Lung metastatic foci enumerated on day 15 post-tumor challenge in
representative mice. Similar trend was noted for n=5 mice/group. Significant differences were observed in panel A (p=0.0082), panel B (p=0.0015)
and panel c (p=0.03) by log-rank test.
doi:10.1371/journal.pone.0032211.g001
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attributed to their proliferative ability. Hence we determined if
CD8
+ T memory cells from FtDKO mice may have reduced
ability to rapidly proliferate in response to antigen. Splenic
cultures from vaccinated mice stimulated in vitro with LM-OVA
and cytokines, and analyzed 4, 6 and 12 days later exhibited a
steady expansion of antigen-specific CD8
+ T cells over time
(Fig. 5B). Moreover, greater number of antigen-specific CD8
+ T
cells was noted for FtDKO cells relative to WT cultures.
Subsequently, the number of OVA257–264-specific CD8
+ T cells
increased in both groups. Thus, the lack of selectin ligands on
CD8
+ T cells did not impair their proliferation.
The infiltration of OVA-specific CD8
+ T cells into the
draining lymph nodes and tumors of FtDKO mice is
impaired
Since FtDKO mice displayed normal antigen-presentation,
CD8
+ T cell expansion, contraction and function, we next
analyzed the tumor infiltrative properties of adoptively transferred
CD8
+ T cells. CD8
+ T cells were expanded in vitro from
vaccinated mice, and then adoptively transferred into non-tumor
and tumor bearing recipients (Fig. 6A). Transfer of equal number
of OVA-specific CD8
+ T cells was done in mice 9 days after tumor
challenge, and mice harbored palpable tumors in the range of
45–90 mm
2. Firstly, significantly greater numbers of
OVA257–264-specific CD8
+ T cells infiltrated the lymph nodes of
WT compared to FtDKO recipients (Fig. 6B and C). This trend
was noted for both non-tumor (Fig. 6B) and tumor bearing
(Fig. 6C) recipients and for WT or FtDKO donor cells. In contrast
FtDKO recipients harbored more donor cells (WT or FtDKO) in
the spleen (Fig. 6D). In WT recipients, FtDKO and WT donor
cells migrated to the lymph node and spleen at similar levels
(Fig. 6B, C & D). Therefore, the FtDKO host environment
appeared to skew the trafficking of donor cells away from the
lymph node compartment. Furthermore, significantly lower
numbers of FtDKO donor cells were recovered from the tumor
tissue of both WT and FtDKO recipients (Fig. 6E). However, high
numbers of donor WT cells were found in tumors of both WT and
FtDKO hosts. Taken together, these results indicate a defect in
homing of antigen specific CD8
+ T cells (WT or FtDKO) to the
lymph nodes of FtDKO recipient mice and compromised
migration of functional selectin ligand-deficient CD8
+ T cells into
the subcutaneous tumor.
Next, we addressed if the lower numbers of FtDKO donor cells
homing to WT tumor was antigen dependant. When OVA-
specific WT or FtDKO donor CD8
+ T cells were transferred into
WT hosts bearing B16 tumors, there was no migration seen to the
tumor indicating that movement of adoptively transferred cells
into the tumor was antigen-dependant (Fig. 7A). Moreover, as
expected the donor cells that migrated to B16-OVA tumor
exhibited antigen-dependant proliferation as evidenced by dilution
Figure 2. Frequency of OVA-CD8
+ T cells following LM-OVA infection. Mice were infected with LM-OVA and challenged with B16-OVA
subcutaneously 21 days (A), 93 days (B) or 126 days (C) post-infection (dpi). Tumor injection time point is indicated by an arrow on the x axis. The
mean 6 SD (n=5 per group) of the frequency of OVA257–264-specific CD8
+ T cells in the blood at various times is indicated (A, B, C). The frequency
blood OVA257–264-specific CD8
+ T cells on day 7 and 21 after LM-OVA infection in individual animals from seven different experiments is presented (D
& E). Representative profile of blood OVA257–264-specific CD8
+ T cell percentages (F). Response on day 7 is statistically different between the two
mouse strains by two tailed, unpaired t test with Welsh’s correction for unequal variance; **, P,0.001, ***, P,0.0001.
doi:10.1371/journal.pone.0032211.g002
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of donor CD8
+ T cells into the tumor tissue, we carried out
adoptive transfer experiments in conjunction with in vivo FTY720
treatment of recipients. FTY720 is a known chemical inhibitor
that blocks egress of lymphoid cells from the lymph node [24].
Fig. 7C shows that in FTY720-treated recipients, there was a
dramatic decrease in the number of donor WT CD8
+ T cells
migrating into the tumor, indicating that tumor infiltrating
donor cells egress from the draining lymph node of the recipient.
Taken together with observations in Fig. 6E, these data suggest
that in the absence of functional selectin ligands on CD8
+ T cells,
the egress of cells from lymph node into the peripheral tumor is
impaired.
Discussion
Adhesion events that occur between antigen-specific CD8
+ T
cells and their environment may influence their initial activation,
maintenance as memory cells, reactivation upon antigenic
encounter, and migration to the tumor site. Among the many
adhesion molecules involved in cell adherence, selectin-selectin
ligand interactions occur early on and mediate rolling and
tethering of lymphocytes along the endothelium. We therefore
surmised that modulation of such mechanisms in FtDKO mice
lacking selectin ligands [25–27] may influence tumor surveillance
by CD8
+ T cells. Induced expression of adhesion molecules such
as chemokine receptors, integrins or selectins on T cells has been
reported to enhance their migration to the periphery [28–30].
Furthermore, reducing the expression of the late adhesion
molecule, VLA-4 on CD8
+ T cells, reduces their recruitment into
tumors [31]. In many cancer models the infiltration of CD8
+ T
cells into a tumor site correlates with improved prognosis [32–34].
Therefore, understanding the events that draw tumor reactive
CD8
+ T cells into a tumor environment is vital for the
development of efficacious anti-tumor vaccines.
Figure 3. Phenotype and functionality of OVA-CD8
+ T cells. C57BL/6J (WT) and FtDKO mice were immunized intravenously with 10
4 LM-OVA.
Representative flow cytometric profile indicating the expression of CD62L and IL-7Ra on OVA257–264-specific CD8
+ T cells on day 7 and 93 and 101 (8
days after tumor challenge) after infection (A). {, Fluorescence minus one (FMO) controls was used to set the gates for IL-7Ra and CD62L. ‘No
antibody control’ indicates gating strategy based on acquisition of cells stained with anti-CD8 antibody and OVA257–264 tetramer but not IL-7Ra or
CD62L antibody. The frequency of TCM (B), TEM (C), and TE (D) of individual replicates at the various time points are shown as a percent of all OVA257–
264-specific CD8
+ T cells. At different time points after infection an in vivo CTL assay was performed in representative mice (n=3 mice per time point
per group), (E). Frequency of IFN-c producing OVA257–264-specific CD8
+ T cells in the spleen (F), liver (G) and inguinal lymph nodes (H) at different time
points after infection is shown. Data in panels F–G represent Mean 6 SD of triplicate ELISPOT wells of n=2 mice per group. This experiment was
repeated 3 independent times with similar results.
doi:10.1371/journal.pone.0032211.g003
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TCM cells and consequent long-term protection against B16-OVA
melanoma [13], providing a convenient model to evaluate the
tenets of anti-tumor immunity. Interestingly, FtDKO mice exhibit
similar kinetics of clearance of Mycobacterium tuberculosis and
Lymphocytic choriomeningitis virus infections in visceral organs
[19,35], despite a disparate frequency of CD8
+ T cells in the
lymph node but similar frequencies in other organs [20,35,36]. In
contrast, FtDKO mice had significantly decreased splenic burden
of LM-OVA as early as 1 day after infection. However, this did
not reduce efficient antigen-presentation by splenic DCs of
FtDKO mice (Fig. 5A). Furthermore, FtDKO mice had severely
enlarged spleens (Fig. S1) possibly due to the increased numbers of
monocytes and neutrophils [17,19]. Moreover, 7 days after LM-
OVA infection, FtDKO mice had significantly higher frequencies
of antigen-specific CD8
+ T cells in the blood. Overall, the
enhanced innate immune response combined with an uncompro-
mised CD8
+ T cell response in the spleens and livers of FtDKO
mice may have contributed to accelerated clearance of LM-OVA
that shows natural tropism for spleen and liver.
The presence of the selectin, CD62L, on antigen experienced
CD8
+ T cells (TCM) correlates with superior tumor protection
[10,12,37]. CD62L is capable of binding a number of cell
associated selectin ligands including glycosylated cell adhesion
molecule-1, CD34, mucosal addressin cell adhesion molecule-1,
sulphated glycoprotein 200, and P-selectin glycoprotein ligand-1
[36,38]. Mice singly deficient in a(1,3) Fucosyltransferase-VII
(FucTVII
2/2) have reduced cell numbers in lymph nodes [17] as
well as reduced CD4
+ and CD8
+ T cell homing into the skin as
shown by a contact hypersensitivity assay [27,36]. However
FucTVII
2/2 mice exhibit an incomplete inhibition of E-selectin
ligand formation. Complete inhibition of selectin ligand binding
including E-selectin interactions occurs in FtDKO mice doubly
deficient for a(1,3) Fucosyltransferase-IV and VII. In this model,
Figure 4. LM-OVA clearance and re-challenge response. Bacterial burden in the spleen (A), and liver (B) of individual mice on different days
post-infection (n=4/time point/group) following intravenous 10
4 LM-OVA infection. **, P=0.0029 by two-tailed t test with Welch’s correction for
unequal variance. In a separate experiment, mice vaccinated with 10
4 LM-OVA were re-challenged 21 days later with 10
5 LM-OVA, (C & D). Splenic
bacterial burden on day 3 following 10
5 LM-OVA infection (C), n=4/group. **, P=0.0013 relative to C57BL/6J by two tailed t-test with Welch’s
correction for unequal variance. The frequency of blood OVA257–264-specific CD8
+ T cells was determined (D) following primary exposure to 10
4 LM-
OVA and re-challenge on day 21 with 10
5 LM-OVA (n=3/group).
doi:10.1371/journal.pone.0032211.g004
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CD8
+ T cell recruitment to the myocardium [26] as well as naive
and memory CD8
+ T cell entry into lymph nodes [19]. We have
shown that despite the normal ability of FtDKO mice to mount a
classic acute immune response to LM-OVA, including induction
of CD62L
high TCM cells, their ability to mediate immune surveillance
against a growing tumor is compromised. Thus, the interaction of
CD62L on CD8
+ T cells with its fucosylated ligands appears to be
important for their ability to infiltrate peripheral tumors.
In a previous study, Vesicular stomatitis virus (VSV) vaccinated
singly deficient FucTVII
2/2 mice challenged intravenously 14 days
later with EL-4N1 (a T cell tumor cell line expressing the viral
nucleoprotein N1) exhibited similar protection as wild-type mice
[36]. However in that study, protection was reported only up to 50
days post tumor challenge. Similarly, we observed that following
intravenouschallengewithB16-OVA, FtDKO micewereprotected
similar to WT controls when observed a few weeks after tumor
challenge. However, later on FtDKO mice succumbed to tumors at
a faster rate relative to controls. Nevertheless, the protection against
metastatic tumor challenge was less severely compromised in
FtDKO mice. This may be attributed to previous observations that
T cell homing to non-lymphoid organs such as lung and liver
remains efficient in the absence of selectin ligand interactions.
Vaccinated FtDKO mice succumbed to tumors at a faster pace
than WT mice when challenged early (day 21) or late (day 126)
post-vaccination. This suggests that the compromised tumor
immunity may not be simply attributed to ineffective maintenance
of the CD8
+ T cell response. Additionally, vaccinated FtDKO
mice exhibited a delay in tumor development relative to non-
vaccinated controls. Thus, selectin ligand deficiency does not
appear to fully negate short-term effector function of antigen-
specific CD8
+ T cells. However, the expression of selectin ligands
is induced on some activated CD8
+ T cells and can play a role in
their extravasation into sites of injury by binding to P-selectin and
E-selectin [18]. Our observation that following adoptive cell
transfer, antigen-specific FtDKO CD8
+ T cells were recovered in
substantially lower numbers in the tumors of WT recipients
suggests that selectin ligand deficient CD8
+ T cells may have an
Figure 5. Antigen presentation and proliferation. Mean 6 SD of triplicate cultures of CFSE reduction correlates to proliferation of OT.1 CD8
+ T
cells in response to DCs from LM or LM-OVA infected mice. Positive controls were pulsed with OVA257–264 peptide in vitro. Data are significantly
different, ***(p,0.0001), relative to negative control (LM infected DCs) by two tailed t test with Welch’s correction for unequal variance. Data are
representative of 2 independent DC isolation experiments. (B) Representative flow cytometric profile indicating in-vitro antigen-dependent
proliferation of OVA257–264-specific CD8
+ T cells on different days of in vitro culture. Samples were obtained from in-vitro cultures in T-75 flasks. Data
are representative of three such independent experiments conducted.
doi:10.1371/journal.pone.0032211.g005
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showing fewer FucTVII
2/2 OVA-specific OT-1 CD8
+ T cells
entering an inflamed footpad compared to WT [26]. However, the
low numbers of FtDKO cells at the tumor site may correlate to a
reduced retention and/or replenishment of these cells over time.
Indeed, lymphoid proliferation of T cells and then peripheral
migration may be required for sustained tumor killing. Schuster et
al [39] showed that naı ¨ve antigen-specific CD62L
2/2 T cells
adoptively transferred to a RAG
2/2 host bearing a MC57-SIY-
IND fibrosarcoma were defective in responding to tumor antigen
and affording protection relative to CD62L
+/+ T cells. Selectin
ligand interactions can influence naive T cell trafficking to lymph
nodes [27,40]. However recently it was postulated that antigen-
experienced CD8
+ T cells can traffic to lymphoid compartments
via other non-high endothelial venules such as afferent lymph [19].
Harp et al reported reduced T cell egress from FtDKO lymph
nodes results in enrichment of CD44
high CD8
+ T memory cells
[19] possibly attributable to differential recirculation of lympho-
cytes in a reduced cell density environment [41]. Overall,
circulating CD8
+ T cells may have directly migrated to highly
vascularized B16-OVA tumors via the blood vasculature, utilizing
selectin ligand independent interactions, thus providing some short-
term protection. However, our results demonstrate that preventing
egress of even WT antigen-specific CD8
+ T cells from lymph nodes
substantially reduces their numbers in tumors. The homing of T
cells to the skin has been shown to be partially dependent on CCR4
[42]. However, we observed that the expression of CCR4 was
similar inWT and FtDKO CD8
+ T cellsat all times after LM-OVA
vaccination (data not shown). Thus, the absence of selectin ligands
alone on the FtDKO CD8
+ T cells may have had a secondary
consequence of abrogating sustained egress of these cells from the
lymph node into the peripheral tumor, compromising long-term
protection. Overall, the presence of selectin ligands on both the host
high endothelial venules and CD8
+ T cells may be important for
efficient and continued extravasation and/or retention within
peripheral tumors such as melanoma.
In the last decade, adoptive T cell transfer-based cancer
immunotherapy has gained prominence in clinical trials including
Figure 6. Migration of Adoptively transferred antigen-specific CD8
+ T cells. Adoptive transfer experiment was carried as indicated in the
schematic diagram (A). Purified CD8
+ T cells from in-vitro antigen-dependant expansion of cultures (comprising 1610
6 OVA257–264-specific CD8
+ T
cells) were transferred intravenously into naı ¨ve or tumor bearing recipient mice (tumor size, 45–90 mm
2) , and donor cells in the various organs of
recipients were enumerated 4 days later. Number of OVA257–264-specific CD8
+ T cells in individual mice recovered from non-tumor bearing lymph
nodes (B), tumor bearing lymph nodes (C) tumor bearing spleen (D) and tumor (E) of recipient WT or FtDKO mice is indicated. (B), *, WT cells in FtDKO
compared to WT hosts, p=0.02; ***, FtDKO cells in FtDKO compared to WT hosts, p=0.0003; **, FtDKO cells compared to WT cells in WT hosts;
p=0.008. (C), *, FtDKO cells in different hosts, p=0.011. (D), *, WT cells in different hosts, p=0.03; * FtDKO cells in different hosts, p=0.036. (E), *,W T
cells compared to FtDKO cells in WT hosts, p=0.034; *, FtDKO versus WT cells in FtDKO hosts, p=0.043. Data were analyzed by unpaired t test.
doi:10.1371/journal.pone.0032211.g006
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affinity T cell receptors of known cancer antigen specificity [43–
45]. Furthermore, focus is shifting towards refining the qualities in
a candidate anti-tumor T cell, such as increased homeostatic
proliferation and increased expression of co-stimulatory molecule
CD27 along with reduced expression of regulatory molecules such
as KLRG-1, CD57 and Eomes such that tumor evasive properties
are effectively counteracted while optimizing the functionality of
anti-tumor T cells [37]. The optimization of selectin ligand
interactions on CD8
+ T cells in such adoptive transfer T cell
preparations may be yet another important criterion for the
maintenance of long-term anti-tumor immunity.
Materials and Methods
Ethics Statement
All animals were housed in the animal facility of the National
Research Council-Institute for Biological Science and maintained
accordingtotheguidelines oftheCanadianCouncilofAnimalCare
(CCAC). Protocols and procedures (Protocol # 2008.24) were
approved and monitored by the National Research Council of
Canada-Institute for Biological Sciences Animal Care Committee.
Bacterial strain and assessment of bacterial burden
LM-OVA was grown as previously described [46]. Spleen and
liver of infected mice were homogenized in 0.9% NaCl and colony
forming units (CFU’s) were determined by plating 100 ml of serial
10-fold dilutions on BHI agar plates (Difco laboratories).
Mice and immunizations
C57BL/6J (WT) mice were obtained from The Jackson
Laboratory. FucT-IV/-VII-deficient (FtDKO) mice on a
C57BL/6J genetic background were generated by Dr. John Lowe
[25] and obtained through the Consortium for Functional
Glycomics, and bred subsequently in-house by homozygote
Figure 7. Effect of tumor antigen and lymph node egress in the migration of adoptively transferred antigen-specific CD8
+ T cells.
Adoptive transfer experiment was carried as indicated in the schematic diagram in Fig. 6A. CFSE-labeled, 1.5610
6 OVA257–264-specific CD8
+ T cells
(obtained from in-vitro expanded cultures) were transferred intravenously into day 9 tumor bearing mice (mean tumor size 45–90 mm
2). Mice were
euthanized 4 days later and the number of donor cells in the various organs of recipients was enumerated. (A), Mean 6 SD (n=3–5/group) of
OVA257–264-specific CD8
+ T cells (of WT or FtDKO origin) recovered from the tumor tissue of WT hosts bearing B16-OVA or B16 tumors respectively is
indicated. *, WT cells in B16-OVA compared to B16 tumor tissue, p,0.05. *, WT cells versus FtDKO cells in B16-OVA tumor tissue, p,0.05. (B),
Representative flow cytometric profile of tumor-infiltrating CD8
+ T cells demonstrating CFSE dilution in WT hosts bearing B16-OVA tumors. (C), Mean
6 SD (n=3–4/group) of OVA257–264-specific CD8
+ T cells (of WT or FtDKO origin) recovered from the tumor tissue of WT hosts that are untreated on
treated with FTY720. *, WT cells in WT hosts compared to WT cells in WT-FTY720 treated hosts, p,0.05.
doi:10.1371/journal.pone.0032211.g007
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thawed and diluted in 0.9% NaCl. Female mice were inoculated
with 1610
4 organisms (unless otherwise indicated) suspended in
200 ml of 0.9% NaCl, via the lateral tail vein.
Murine Melanoma model
B16 and B16-OVA (expressing plasmid derived ovalbumin) cells
were obtained from Dr. Edith Lord (University of Rochester,
Rochester, NY). B16-OVA cells were cultured in RPMI 1640
medium supplemented with 8% Fetal Bovine Serum (FBS)
containing 400 mg/ml of G418 (for plasmid antibiotic selection)
and 10 mg/ml of gentamicin. B16-OVA cells (1610
6 in PBS+0.5%
normal mouse serum) were injected subcutaneously in the shaven
lower dorsal region of mice. From day 5 onwards, detectable solid
tumor was measured using calipers. Tumor size, expressed in
mm
2, was obtained by multiplication of diametrically perpendic-
ular measurements. End-points for the survival graphs were based
on a maximum tumor size of 200 mm
2. For the metastatic model,
B16-OVA cells (5610
5) were injected intravenously via the lateral
tail vein. Mice were euthanized 15 days later for enumeration of
black lung tumor foci. Conversely, survival was determined based
on 20% loss in body weight or visible clinical signs of illness such as
piloerection, hunched posture and lethargy.
Assessment of phenotype of OVA257–264-specific CD8
+ T
cells
At various time intervals after infection, 50 ml aliquots of whole
blood was incubated with anti-CD8 (clone 53-6.7, BD Pharmin-
gen), anti-CD62L (clone MEL-14, BD Pharmingen), anti-IL-7Ra
(CD127, clone A7R34, BD Pharmingen) antibody and H-
2K
bOVA257–264 tetramer (Beckman Coulter) diluted in PBS plus
1% bovine serum albumin (PBS-BSA) for 30 min. Red blood cells
were lysed and cells were washed with PBS, fixed in 1% formal-
dehyde, and acquired on BD Biosciences FACS Canto analyzer.
Assessment of CD8
+ T cell function
In vivo cytolytic activity of antigen-specific CD8
+ T cells was
enumerated as described previously [47]. Briefly, infected recipient
mice were injected with a 1:1 mixture of differentially labeled
OVA257–264 peptide-target and control cells. The survival
proportions of donor cell populations in recipient spleens were
determined 24 h later, and percentage in vivo killing calculated.
Enumeration of IFN-c-secreting cells was performed by ELISPOT
assay [46]. Liver lymphocytes were obtained after tissue
homogenization and percoll (GE Healthcare Biosciences) density
gradient centrifugation. Lymphocytes (at a final density of 5610
5
cells/well by using feeder splenocytes) were incubated on anti-
IFN-c-antibody-coated ELISPOT plates and stimulated with
OVA257–264 peptide (10 mg/ml) in RPMI+8% FBS containing
IL-2 (0.01 ng/ml), for 48 h at 37uC, 8% CO2. Plates were then
washed (0.01% Tween in PBS) and incubated with the
biotinylated secondary antibody (2 h at 37uC), followed by
streptavidin-horse radish peroxidase conjugate (1 h at room
temperature). Spots were developed using AEC (3-amino-9-
ethylcarbazole) peroxidase substrate solution.
CD8
+ T cell primary cultures and adoptive transfer
experiments
Splenocytes (10
8) pooled from infected mice (n=2–3) were
stimulated with 10
4 LM-OVA in-vitro and cultured in 10 ml
RPMI+8% FBS in T-25 tissue culture flasks (Falcon), at 37uC and
8% CO2. Gentamicin (50 mg/ml) was added to the cultures 15 h
later to kill any live LM-OVA. Subsequently at 40 h after in-vitro
antigen exposure, cells were transferred in fresh media supple-
mented with IL-7 and IL-15 (1 ng/ml) to a T-75 tissue culture
flask and thereafter expanded with media and cytokine supple-
mentation every two days. For analysis of proliferation, a sample of
cells was retrieved on various days after culture and analyzed for
the expression of OVA257–264-tetramer-specific CD8
+ T cells by
flow cytometry. For adoptive transfer experiments, CD8
+ T cells
were purified from day 13 cultures expanded as detailed above
using CD8
+ T cell negative enrichment kit (STEMCELL Inc.).
Equal number of antigen-specific CD8
+ T cells (deduced from flow
cytometric analysis of in-vitro cultures) of either WT or FtDKO
phenotype were injected (i.v.) into naı ¨ve or day 9 tumor bearing




Mice were injected intraperitoneally (i.p.) with 1 mg/Kg FTY720
(Selleck Chemicals) in 200 ml (diluted in PBS after dissolution of the
compound in a small volume of DMSO) 24 h after adoptive transfer
ofantigen-specificCD8
+Tcellsandthenevery24 huntileuthanasia
of mice and harvest on day 4 after adoptive transfer.
Dendritic cell purification and assessment of antigen
presentation
Spleen cells were obtained from mice 1 day after 10
4 LM or
LM-OVA infection and treated with spleen dissociation medium
(STEMCELL Inc.). Dendritic cells (DC’s) were purified using the
positive selection DC purification kit (STEMCELL Inc.) that
consistently, 80–84% purity. DCs (3610
5/well) were co-cultured
for 4 days with CFSE (0.125 mM) stained splenocytes obtained
from OT.1 mice (10
5 per well), in u-bottom 96-well microtiter
plates, in RPMI+8% FBS and 50 mg/ml gentamicin. OT.1 mice
are transgenic for the TCR of OVA and harbor .99% OVA-
specific CD8
+ T cells in their lymphoid organ. Positive controls
included cells cultured with 5 mg/mL of OVA257–264 peptide.
Proliferation of CD8
+ T cells was measured 4 days later by
assessing CFSE reduction by flow cytometry.
Supporting Information
Figure S1 Mice (WT and FtDKO) were infected (i.v.)
with 10
4 LM-OVA. Spleens were isolated at varying time points
after infection and enumerated for numbers of lymphocytes by
microscopy with trypan blue staining. n=3–4 mice/group/time-
point.
(TIF)
Figure S2 Mice (WT and FtDKO) were infected (i.v.)
with 10
3 or 10
4 LM-OVA respectively. (A), Spleens were
removed on day 1, 3 or 5 after infection and bacterial burden was
determined (n=3–4 mice). (B), another group of infected mice
were challenged with 10
6 B16-OVA and survival based on a
maximum tumor size of 300 mm
2 was monitored. Data is
compiled from two separate studies. Median survival of vaccinated
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